MPI Launches DNA Microarray Services

Medical Prognosis Institute launches their gene expression analysis with DNA microarrays and expands with two new key employees.

Medical Prognosis Institute (MPI) is now launching their gene expression analysis with DNA microarrays. The DNA microarray services is being offered to biopharmaceutical companies targeting a broad array of diseases where superior quality gene expression analysis is an important tool in making the drug discovery process more effective and informative.

Furthermore, MPI is expanding with two employees, Jesper Dahlgaard and Wiktor Mazin. Jesper Dahlgaard, Ph.D., will as a Senior Scientist manage MPI's clinical trials as well as research collaborations and research contracts, and Wiktor Mazin, Ph.D., will be Head of Bioinformatics.

MPI has a strong record of performing DNA microarray analysis of mouse and human samples, and currently has two products in phase III clinical trials. MPI is headquartered in Hørsholm, Denmark.

Source: Press release, Medical Prognosis Institute, 09.03.2008